Poignet J L, Desassis J F, Chanton N, Litchinko M B, Zins B, Kolko A, Patte R, Sobel A
Clinique médicale Edouard Rist, Paris.
Nephrologie. 1999;20(3):159-63.
In order to determine the prevalence of HIV infection in french patients with end-stage renal disease (ESRD) on maintenance dialysis therapy, questionnaire forms were mailed out in february 1997 to the heads of the 260 dialysis facilities. We documented number of patients on maintenance dialysis therapy (hemo and peritoneal dialysis) and for HIV infected dialysis patients: age, gender, cause and duration of ESRD, known duration of HIV infection, risk factors for HIV infection, HBV and/or HCV infection, presence of clinical acquired immunodeficiency syndrome (AIDS), total CD4 count and treatment with antiretroviral agents. Questionnaire forms were returned from 98% of the dialysis facilities. As of february 1997 some 22,707 patients with ESRD were treated by renal replacement therapy, 19,947 by hemodialysis (HD) and 2760 by peritoneal dialysis (PD). 82 patients with ESRD and HIV infection were reported corresponding to 0.36% prevalence rate of all patients undergoing dialysis at the time specified. The 82 study subjects with ESRD and HIV infection received hemodialysis (79 patients) or peritoneal dialysis (3 patients) in 42 facilities. Forty seven patients were treated in Paris and suburbs and 9 in our own center. All 82 patients comprised 63% men and 47% women which included patients coming from Africa (37%), Caribbean and Oceania (28%), Europe (35%) of a mean age of 41.8 years. Modes of transmission were homobisexuals 15%, heterosexuals 31%, intravenous drug abusers 17%, blood transfusion 17% and unknown 20%. The mean duration of HIV infection was 96 months (range 12-168 months) and the mean duration of ESRD was 58 months (range 1-235 months). HIV associated nephropathy was established in 31%. AIDS was diagnosed in 25 patients. Seventy one percent of the patients were receiving an antiretroviral drug (tritherapy in 25% of cases). In conclusion HIV prevalence rate among French dialysis patients is low and focused in Paris and oversea. Sexual transmission is the most important HIV contamination but blood transfusion transmission remains greater than in general HIV population. Survival has improved compared with the survival rate reported in the 1980s.
为了确定接受维持性透析治疗的法国终末期肾病(ESRD)患者中HIV感染的患病率,1997年2月向260家透析机构的负责人邮寄了调查问卷。我们记录了接受维持性透析治疗的患者数量(血液透析和腹膜透析)以及HIV感染的透析患者的情况:年龄、性别、ESRD的病因和病程、已知的HIV感染病程、HIV感染的危险因素、HBV和/或HCV感染、临床获得性免疫缺陷综合征(AIDS)的存在情况、总CD4计数以及抗逆转录病毒药物治疗情况。98%的透析机构返回了调查问卷。截至1997年2月,约22,707例ESRD患者接受了肾脏替代治疗,其中19,947例接受血液透析(HD),2760例接受腹膜透析(PD)。报告了82例ESRD合并HIV感染的患者,占指定时间接受透析的所有患者的患病率为0.36%。82例ESRD合并HIV感染的研究对象在42家机构接受血液透析(79例患者)或腹膜透析(3例患者)。47例患者在巴黎及其郊区接受治疗,9例在我们自己的中心接受治疗。82例患者中男性占63%,女性占47%,其中包括来自非洲的患者(37%)、加勒比和大洋洲的患者(28%)、欧洲的患者(35%),平均年龄为41.8岁。传播途径为男同性恋者占15%,异性恋者占31%,静脉吸毒者占17%,输血占17%,不明占20%。HIV感染的平均病程为96个月(范围12 - 168个月),ESRD的平均病程为58个月(范围1 - 235个月)。31%的患者确诊为HIV相关性肾病。25例患者被诊断为AIDS。71%的患者正在接受抗逆转录病毒药物治疗(25%的病例接受三联疗法)。总之,法国透析患者中的HIV患病率较低,集中在巴黎和海外。性传播是最重要的HIV感染途径,但输血传播仍然高于一般HIV人群。与20世纪80年代报告的生存率相比,生存率有所提高。